UP
Insider
UBS Oncology Impact Fund L.P.
10% ownerUBS Oncology Impact Fund L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (0 purchases, 1 sale), most often in Werewolf Therapeutics, Inc. (HOWL). The largest single filing was $446K of HOWL (276,017 sh across 3 lots, as filed), executed Oct 27 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
1
0 buys · 1 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$446K
shares × price, as filed
Last traded
Oct 29 2025
Filed Oct 29 2025
Median ADV $290K across their filed names
Open performance→Volume by month
Buys $0
Sells $446K
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
HOWLRecent filings
HOWLSALE
Werewolf Therapeutics, Inc.
View filing →
$446K276,017 sh across 3 lots
Exec Oct 27 2025
Filed Oct 29 2025 · 5:30 PM ET